UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

Glaxosmithkline, which has major operations in Montgomery County, is set to receive a major settlement, writes Anthony O. Goriainoff for the Wall Street Journal. The pharmaceutical powerhouse will ...

GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million. Meanwhile, the EPS declined to EGP 0.85 from EGP 1.19. In April-June 2025, ...

Less than two months after GlaxoSmithKline pledged to cap out-of-pocket costs, Sen. Maggie Hassan (D-N.H.) is accusing the company of circumventing that vow.

GlaxoSmithKline GSK (GSK), Europe's largest drugmaker, said second-quarter net income slipped to 1.29 billion pounds ($2.6 billion) from 1.33 billion pounds, with revenue rising to 5.87 billion ...

GSK expects both core operating profit and core EPS to grow in the range of 6-8% including the impact of the share buyback program. R&D is expected to increase at a rate similar to sales growth.

Glaxo (GSK) rejects an offer from Unilever to acquire its consumer business worth 50 billion pounds ($68 billion). However, Unilever is likely to pursue the acquisition of the business.

GSK also recorded sales of £1 million from its share of contracted European volumes of COVID-19 booster vaccine, co-developed in partnership with Sanofi. Sales rose 34%, excluding COVID-19 solutions.